Research community previously filed under “Public Health, Environmental and Occupational Health”

Antileishmanial Drug Discovery and Resistance Mechanisms

Papers 9,671
Elements 1
Keywords & sectors 2
Leading venue PLoS neglected tropical diseases

Antileishmanial Drug Discovery and Resistance Mechanisms

This community focuses on developing new treatments for leishmaniasis, a group of parasitic diseases, and understanding why current drugs fail. The work combines the design of new chemical compounds with clinical studies on how the parasite develops resistance to existing therapies.

The research centers on identifying molecules that inhibit Leishmania species, particularly L. infantum, L. major, and L. donovani. Recurring methods include molecular docking, virtual screening, and the synthesis of chemical derivatives to test for antileishmanial activity. The community also investigates drug resistance mechanisms and evaluates the efficacy of standard treatments like meglumine antimoniate and sodium stibogluconate. While Trypanosoma cruzi and Plasmodium falciparum appear in the literature, the core focus remains on leishmaniasis, with a specific emphasis on cutaneous and visceral forms of the disease.

The largest share of the community's output is found in antimony research, accounting for 2.6% of all antimony research, and 1,171 papers here. Sodium and oxygen also appear frequently, with 574 and 340 papers respectively, reflecting the chemical composition of standard antimonial drugs.

The community comprises 9,671 papers, publishing primarily in PLoS neglected tropical diseases, Antimicrobial Agents and Chemotherapy, and Memórias do Instituto Oswaldo Cruz.

Recent work continues to focus on leishmaniasis, including studies on drug resistance mechanisms, vaccine development, and the evaluation of new chemical derivatives through in silico and in vitro methods.

Recurring themes in the literature

Phrases that recur across this community's paper titles -- a quick map of its sub-topics, drawn straight from the titles themselves.

  • cutaneous leishmaniasis 343
  • visceral leishmaniasis 195
  • leishmania infantum 133
  • leishmania major 116
  • leishmania donovani 115
  • molecular docking 112
  • against leishmania 87
  • leishmania amazonensis 75
  • treatment cutaneous 72
  • case report 66
  • trypanosoma cruzi 64
  • design synthesis 61
  • leishmania tropica 60
  • vitro vivo 59
  • antileishmanial activity 58
  • meglumine antimoniate 57
  • leishmania viannia 49
  • plasmodium falciparum 47
  • leishmania braziliensis 42
  • drug resistance 41
  • chagas disease 38
  • drug discovery 38
  • virtual screening 35
  • molecular dynamics 34

Papers behind this description

Most cited
American Journal of Clinical Dermatology · 2022 · 358 citations
PLoS neglected tropical diseases · 2025 · 83 citations
Saudi Journal of Biological Sciences · 2023 · 134 citations
Nature Reviews Microbiology · 2022 · 182 citations
Malaria Journal · 2022 · 207 citations
Newest
ADMET & DMPK · 2026 · 8 citations
Biomedicines · 2025 · 8 citations
In Silico Pharmacology · 2025 · 8 citations
PLoS Pathogens · 2026 · 5 citations
UMYU Scientifica · 2025 · 6 citations

A sample from the 14 papers behind this description. Create a free account to see them all.